How India Exports Ledipasvir to the World

In the United States, the combination of ledipasvir and sofosbuvir is marketed under the brand name Harvoni. The FDA approved Harvoni on October 10, 2014, for the treatment of chronic HCV infection in adults. Subsequent approvals expanded its use to pediatric patients aged 12 and older on April 7, 2017, and to those aged 3 to 11 on August 28, 2019.

As of March 2026, the FDA's Orange Book does not list any approved Abbreviated New Drug Applications (ANDAs) for generic versions of ledipasvir/sofosbuvir, indicating the absence of generic competition in the U.S. market. Additionally, there are no current import alerts related to ledipasvir, suggesting compliance with FDA regulations by exporters. Given that 60 Indian exporters are actively involved in the international trade of ledipasvir, the absence of generic approvals in the U.S. presents a potential market opportunity for these manufacturers.

The European Medicines Agency (EMA) granted marketing authorization for Harvoni on November 17, 2014, for the treatment of chronic HCV in adults and pediatric patients aged 3 years and above. (ema.europa.eu) The UK's Medicines and Healthcare products Regulatory Agency (MHRA) adopted this authorization prior to Brexit. Post-Brexit, the MHRA continues to recognize EMA approvals unless specific changes are announced.

Manufacturers exporting ledipasvir to the EU and UK must comply with Good Manufacturing Practice (GMP) standards as outlined by the EMA and MHRA. These standards ensure product quality and safety, necessitating regular inspections and adherence to stringent manufacturing protocols.

Ledipasvir, in combination with sofosbuvir, is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its significance in global health. The combination is also subject to WHO Prequalification, a program that assesses the quality, safety, and efficacy of medicinal products. Compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is essential for manufacturers to meet global quality benchmarks.

In India, ledipasvir is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines. As of March 2026, ledipasvir is not listed under the DPCO, allowing manufacturers to set prices based on market dynamics. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with international trade regulations.

The primary patent for the combination of ledipasvir and sofosbuvir expired in October 2024, concluding the exclusivity period. This expiration opens the market to generic competition, providing opportunities for Indian exporters to supply cost-effective alternatives to global markets.

In June 2025, the EMA released revised bioequivalence guidelines for ledipasvir/sofosbuvir formulations, emphasizing the need for comprehensive studies to ensure therapeutic equivalence. (ema.europa.eu) In September 2025, the WHO updated its Essential Medicines List, reaffirming the inclusion of ledipasvir/sofosbuvir, highlighting its continued importance in HCV treatment protocols. In December 2025, the NPPA conducted a review of antiviral drug prices, including ledipasvir, to assess market trends and ensure affordability. In January 2026, the DGFT streamlined the export NOC process for pharmaceutical products, aiming to facilitate smoother international trade for Indian exporters. In February 2026, the CDSCO issued a notification reinforcing the requirement for bioequivalence studies for generic versions of ledipasvir/sofosbuvir, ensuring consistent therapeutic outcomes.

These developments reflect a dynamic regulatory environment, with ongoing efforts to balance innovation, accessibility, and quality in the pharmaceutical sector.

Ledipasvir, an antiviral agent used in the treatment of hepatitis C, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) often relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a dominant player in the pharmaceutical raw material market.

The reliance on Chinese KSMs introduces significant supply chain vulnerabilities. For instance, in October 2025, the U.S. Pharmacopeia reported that 41% of KSMs used in U.S.-approved APIs are solely sourced from China, highlighting the global dependence on Chinese suppliers. Any disruptions in China's production capabilities, whether due to geopolitical tensions, environmental regulations, or other factors, can lead to substantial delays and increased costs in API manufacturing for drugs like Ledipasvir.

Our proprietary trade data indicates that the top five Indian exporters account for 85.5% of Ledipasvir exports, with HETERO LABS LIMITED alone contributing 58.1% of the total export value. This high concentration poses a significant single-source risk, as any operational or regulatory issues faced by these key suppliers could disrupt the global supply chain for Ledipasvir.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, aiming to boost domestic manufacturing of critical KSMs, Drug Intermediates (DIs), and APIs. As of December 2025, the scheme has led to the creation of manufacturing capacity for 26 KSMs/APIs, resulting in cumulative sales of ₹2,315 crore and avoiding imports worth ₹1,807 crore. While this initiative is a positive step towards reducing import dependency, its impact on the Ledipasvir supply chain remains to be fully realized.

The global pharmaceutical supply chain is susceptible to geopolitical tensions and shipping disruptions. For instance, the Red Sea and the Strait of Hormuz are critical maritime routes for shipping raw materials and finished pharmaceutical products. Any instability in these regions can lead to delays and increased shipping costs. Additionally, ongoing U.S.-China trade tensions have raised concerns about the reliability of Chinese KSM supplies, further exacerbating supply chain vulnerabilities.

Regulatory bodies like the U.S. Food and Drug Administration (FDA) have issued warning letters to API manufacturers in China and India for significant deviations from current Good Manufacturing Practice (cGMP). In February 2025, the FDA flagged Indian API manufacturer Global Calcium for cGMP violations, underscoring ongoing quality concerns and the potential for supply disruptions.

• Diversify Supplier Base: Engage with multiple API and KSM suppliers across different geographies to reduce dependency on a single source.

• Strengthen Domestic Manufacturing: Leverage government initiatives like the PLI Scheme to enhance local production capabilities for critical KSMs and APIs.

• Enhance Quality Compliance: Implement stringent quality control measures to ensure compliance with international cGMP standards, thereby reducing the risk of regulatory actions.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on the supply chain, enabling proactive risk management.

• Develop Contingency Plans: Create comprehensive contingency plans, including alternative shipping routes and emergency stockpiles, to mitigate the effects of potential disruptions.

RISK_LEVEL: MEDIUM